Vaccine induced protection against hepatitis B

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7380.105 (Published 11 January 2003) Cite this as: BMJ 2003;326:105
  1. Pierre Van Damme, professor (pierre.vandamme@ua.ac.be),
  2. Jangu E Banatvala, emeritus professor of clinical virology
  1. Department of Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein, 1, B-2610 Wilrijk, Belgium
  2. Guy's, King's College, and St Thomas's School of Medicine and Dentistry, London

    EDITOR—Whittle et al report one of the few long term follow up studies of children vaccinated against hepatitis B.1 The reported reduction in the rate of carriers of hepatitis B surface antigen in two villages in the Gambia, from 13% to 1% and from 35% to 2% respectively, represents a major achievement in public health.

    We are concerned, however, that those who are influential in deciding policy of hepatitis B vaccination may not appreciate that relevant information is missing in …

    View Full Text

    Sign in

    Log in through your institution